Men's Health Programme Mohali — Testosterone, Heart Health, Hormones & Beyond

We recommend starting at 35, or earlier if symptoms are present. By 40, baseline hormone and cardiac risk assessment is strongly advisable — it gives you a reference point as you age and catches early problems when they're easiest to treat. Men who present at 50 or 55 with significant testosterone deficiency or cardiac risk have typically been accumulating these problems for 10–15 years. Early detection allows early, low-intensity intervention. The AndroScore assessment is designed specifically as a first step for men who want to be proactive rather than reactive.

When monitored properly by an endocrinologist and urologist together — yes. At Gini, TRT is managed with 3-monthly testosterone, haematocrit, PSA, and lipid monitoring. We do not start TRT without baseline cardiac risk assessment. Long-term safety data from well-monitored trials is reassuring. The concerns historically associated with TRT — prostate cancer risk, cardiovascular events — have not been borne out in appropriately selected and monitored patients in the modern literature. The TRAVERSE trial (2023) showed no increased cardiovascular risk in men on TRT with properly controlled metabolic factors. The key word is monitoring: TRT without monitoring is not safe medicine — TRT with monitoring is standard endocrine care.

Low testosterone is an independent risk factor for metabolic syndrome, insulin resistance, visceral fat accumulation, and cardiovascular events. Correcting it — appropriately, under monitoring — is associated with improved cardiac risk markers, not worsened ones. The fear is about supraphysiological testosterone (bodybuilding doses, performance use) — not therapeutic replacement that restores levels to the mid-normal physiological range. Men with symptomatic hypogonadism who are left untreated have consistently worse cardiovascular outcomes than those treated and monitored. This is one of the most important messages Dr. Bhansali emphasises in his endocrinology practice.

Men with diabetes have 3× the rate of ED due to neuropathy (nerve damage), vascular damage, and low testosterone secondary to insulin resistance. ED in a diabetic man is a serious early warning sign of cardiovascular risk — the penile vasculature reflects the health of the coronary and carotid vasculature. At Gini, we treat both simultaneously and do not separate them. Dr. Bhansali's team manages glucose optimisation, insulin sensitisation, and where appropriate GLP-1 therapy — while Dr. Aggarwal manages the sexual function component. Men who achieve tight glucose control often see meaningful improvement in erectile function without any specific ED treatment.

Dr. Aggarwal conducts a full infertility workup: semen analysis by WHO 2021 criteria, hormonal profile (FSH, LH, testosterone, prolactin), scrotal ultrasound for varicocele, and genetic testing (karyotype, Y-chromosome microdeletion) where indicated. The cause of azoospermia — whether obstructive or non-obstructive — determines the surgical approach. Obstructive azoospermia is treated with PESA or TESA. Non-obstructive azoospermia — where sperm production is impaired — requires microdissection TESE (mTESE), a microsurgical procedure that Dr. Aggarwal performs with sperm retrieval rates of 40–60% even in the most challenging cases. Retrieved sperm is used for ICSI at partner IVF labs.

Yes — injectable testosterone (enanthate, undecanoate) and transdermal gels are fully available in India and are standard medications. Injectable TRT starts at approximately ₹4,000/month including monitoring consultations. Dr. Bhansali and Dr. Aggarwal manage TRT together to ensure endocrine and urological oversight — no patient is prescribed testosterone by one doctor without the other being aware of their cardiovascular and prostatic profile. We do not use unregulated testosterone supplements or sports-use formulations. All prescriptions are from licensed pharmaceutical manufacturers and are administered in or supervised by our clinical team.

A general health check gives you lab results. Our programme gives you a personalised protocol — diet, exercise, medication, TRT if needed, and regular monitoring with outcomes tracked over time. Every patient's status is measured at each visit and compared to their baseline. The difference is between data and action. Most "executive health checks" produce a 12-page PDF that the patient reads once and puts in a drawer. Gini's programme produces a clinical protocol that is reviewed and updated every three months, with measurable targets for testosterone, HbA1c, lipids, and body composition. That is the difference between a health check and a health programme.